Journals / Journal of Experimental and Clinical Medicine / 2013 / Cilt: 30 - Sayı: 2

Assessment of ovarian tumor marker CA-125 during radiotherapy course

Pages
137–139
Publication Date
2013-07-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also there is significant relationship between the cancer stage and the level of antigen CA-125 (R2=0.98).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The antigen secretion by ovarian cancer (CA-125) has been assessed using Radio Immune Assay (RIA) technique among a hundred ovarian cancer patients who received radiotherapy course as radical treatment.
📊
Key Findings & Data:The study revealed that, the ovarian cancer commonly associated with the age groups of 30-40 years old taking a percent of 68 relative to other age groups and the antigen CA-125 does not has relation with aging.
💡
Conclusion & Impact:Also there is significant relationship between the cancer stage and the level of antigen CA-125 (R2=0.98).
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Ovarian cancer · Radiation therapy and tumor maker · Radioimmuneassay

Abstract

The antigen secretion by ovarian cancer (CA-125) has been assessed using Radio Immune Assay (RIA) technique among a hundred ovarian cancer patients who received radiotherapy course as radical treatment. The study revealed that, the ovarian cancer commonly associated with the age groups of 30-40 years old taking a percent of 68 relative to other age groups and the antigen CA-125 does not has relation with aging. While the radiotherapy shows it is efficiency in management of ovarian cancer by reducing the antigen CA-125 level from 134 ± 13.3 U/ml to 5.5 ± 2.1 U/ml relative to normal level of CA-125 (35 U/ml). Also there is significant relationship between the cancer stage and the level of antigen CA-125 (R2=0.98).

🔖

Cite This Article

ALIOMER, M., MOHAMED, M., YOUSEF, M., FARAHNA, M., ALGHANIM, A. (2013). Assessment of ovarian tumor marker CA-125 during radiotherapy course. Journal of Experimental and Clinical Medicine, Cilt: 30 - Sayı: 2, 137–139. https://ajindex.com/articles/678634

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. ACOG: American College of Obstetricians and Gynecologists, 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet. Gynecol. 100, 1413-1416. American Cancer Society. Cancer Facts and Figures. (2012).
  2. Atlanta, GA. Bast, R.C. Jr., Feeney, M., Lazarus, M., Nadler, L.M., Colvin, R.B., Knapp, R.C., 1981. Reactivity of a monoclonal antibody with human ovarian carcinoma. J. Clin. Invest. 68, 1331-1337.
  3. Bast, R.C. Jr., Klug, T.L., ST. John, E., 1983. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med., 308, 883-887.
  4. Bhattacharya, M., Chatterjee, S.K., Barlow, J.J., Fuji, H. 1982. Monoclonal antibodies recognizing Tumour-associated antigens of human ovar- ian mucinous cystadenocarcinomas. Cancer Res. 42, 1650-1654.
  5. Canney, P.A., Moore M., Wilkinson, P.M., James, R.D., 1984. Ovarian cancer antigen CA125: A prospective clinical assessment of its role as a tumor marker. Brth. J. Cancer. 50, 765-769.
  6. Coussy, F., Chéreau, E., Daraï, E., Dhombres, F., Lotz, J.P., Rouzier, R., Selle, F., 2011. Interest of CA 125 level in management of ovarian can- cer. Gynecol. Obstet. Fertil. 39, 296-301.
  7. Donaldson, E.S., Van Nagell, J.R., Pursell, S., 1980. Multiple biochemical markers on patients with gynaecologic malignancies. Cancer. 45, 948-953.
  8. Goone Wardene, T.I., 2007. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 8, 813-821.
  9. Gregory, P. Beehler., Manveen S., Julie, A. B., Barbara E. T., Susan, E. M., Kerry J. R., and Kirsten B. M., 2006. Risk of ovarian cancer associ- ated with BMI varies by menopausal status.J. Nutr. 136, 2881–2886.
  10. Hogdall, E., 2008. Cancer antigen CA-125 and prognosis. Curr. Opin. Obstet. Gynecol. 20, 4-8.
  11. Keys, A., Fidanza, F., Karvonen, M.J., Kimura, N., Taylor, H.L., 1972. Indices of relative weight and adiposity. J. Chronic. Dis. 25, 329-343.
  12. Kramer, J.L., Greene, M.H., 2004.
  13. Epidemiology of Ovarian, Fallopian Tube, and Primary Peritoneal Cancers. in: Gynecologic Cancer: Contro- versies in Management. Gershenson, D., Gore, M., McGuire, W., Quinn, M., Thomas, G., editors. Elsevier Science. pp. 327-340.
  14. Manolov, V., Marinov, B., Vasilev, V., 2012. HE4 and CA125 in ovarian cancer. Akush. Ginekol. 51, 21-28. NCCN: National Comprehensive Cancer Network, 2009. NCCN Practice Guidelines in Oncology: Ovarian cancer, Vol. 2. Rustin, G.J.S., Nelstrop, A.E., Bentzen, S.M., Piccart, M